809 results on '"Vigano', M."'
Search Results
302. Surgical therapy for chronic thromboembolic pulmonary hypertension: criteria for choosing lung transplant vs trhomboendarterectomy
303. CLINICAL EXPERIENCE WITH THE CONTINOUS FLOW MICROMED DEBAKEY VADTM
304. The European experience of Novacor left ventricular assist (LVAS) therapy as a bridge to transplant: a retrospective multi-centre study
305. Balancing import and export in development
306. Multiple coronary thrombosis and allograft vascular disease
307. Satisfactory recovery and viability of stem cells cryopreserved at high cell concentration
308. Effectiveness of Leukocyte Filters in Reducing Tumor Cell Contamination after Intraoperative Blood Salvage in Lung Cancer Patients
309. 777 INCIDENCE AND CLINICAL CONSEQUENCES OF REDUCED TUBULAR PHOSPHATE RE-ABSORPTION (TmPO4/GFR) IN NAÏVE CHRONIC HEPATITIS B PATIENTS TREATED WITH TENOFOVIR: A TWO-YEAR FIELD STUDY
310. 755 5-YEAR ENTECAVIR TREATMENT IN NUC-NAÏVE, FIELD-PRACTICE PATIENTS WITH CHRONIC HEPATITIS B SHOWED EXCELLENT VIRAL SUPPRESSION AND SAFETY PROFILE BUT NO PREVENTION OF HCC IN CIRRHOTICS
311. F-13 Switching to tenofovir is safe in most CHB patients with a reduced glomerular filtration rate due to previous exposure to adefovir dipivoxil
312. T-12 Tenofovir suppressed viral suppression in most field practice, treatment-naïve patients with CHB followed for 3 years in a multicenter European study
313. T-11 5-year entecavir in NUC-naïve, field-practice patients with CHB showed excellent viral suppression and safety but no prevention of HCC
314. OC-30 Incidence and clinical consequences of reduced tubular phosphate re-absorption in naïve CHB patients treated with tenofovir: a two-year field study
315. Transcriptional activation by Oct-3: evidence for a specific role of the POU-specific domain in mediating functional interaction with Oct-1
316. Determinants of heart rate variability in heart transplanted subjects during physical exercise
317. Surgery for atrial fibrillation
318. Different results of cardiac transplantation in patients with ischemic and dilated cardiomyopathy
319. Heterotopic heart transplantation: three dimensional image
320. T-cell count and antilymphocyte globulin therapy
321. Right Atrial Isolation Associated with Atrial Septal Closure in Patients with Atrial Septal Defect and Chronic Atrial Fibrillation
322. Emergency and elective cardiac retransplantation
323. Optimization of Sampling Time for Cyclosporine Monitoring in Transplant Patients
324. Heart and heart-lung transplantation: The present situation
325. Right ventricular failure after heart transplantation: relationship with preoperative haemodynamic parameters
326. Human umbilical cord blood mesenchymal stem cells protect mice brain after trauma.
327. Long term survival after heart transplantation for doxorubicin induced cardiomyopathy.
328. Oct-3 and the Beginning of Mammalian Development
329. SOLUBLE INTERLEUKIN-2 RECEPTOR IN HEART TRANSPLANT RECIPIENTS
330. 649 Study Design and Preliminary Results of the Italian Everolimus Registry CERTIC
331. 448 Heart Transplantation for End-Stage Valvular Cardiomyopathy: A 26-Year Single-Center Experience
332. 545 DECLINE OF BONE MINERAL DENSITY DURING LONG-TERM NUCLEOS(T)IDE ANALOG THERAPY: A LONGITUDINAL COHORT STUDY OF 135 PATIENTS WITH CHRONIC HEPATITIS B
333. 524 RESPONSE-GUIDED PEGINTERFERON ALFA-2A THERAPY BASED ON HBSAG LEVELS AT WEEK 12 AND WEEK 24 OR 48 IMPROVES RESPONSE RATES IN HBEAG-NEGATIVE, GENOTYPE D PATIENTS
334. 523 ADD-ON PEG-IFN IMPROVES HBSAG KINETICS IN PATIENTS LONG-TERM FULLY SUPPRESSED BY NUCLEOS(T)IDE ANALOGS
335. 525 TENOFOVIR MONOTHERAPY FOR NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE IN 302 PATIENTS FOLLOWED FOR 30 MONTHS
336. 522 MAINTAINED VIRAL SUPPRESSION AND EXCELLENT SAFETY PROFILE OF ENTECAVIR MONOTHERAPY IN 418 NUC-NAÏVE PATIENTS WITH CHRONIC HEPATITIS B: A 4-YEAR FIELD PRACTICE, MULTICENTER STUDY
337. P.15.2 ENTECAVIR MONOTHERAPY IN 418 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B FROM FIELD PRACTICE: HIGH EFFICACY AND FAVORABLE SAFETY PROFILE OVER 3 YEARS OF TREATMENT
338. P.04.5 THE COURSE OF BONE MINERAL DENSITY IN PATIENTS WITH CHRONIC HEPATITIS B LONG TERM TREATED WITH NUCLEOS(T)IDE ANALOGS: A LONGITUDINAL COHORT STUDY
339. OC.07.1 2-YEAR EFFECTIVENESS AND SAFETY OF TENOFOVIR IN 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B: A MULTICENTER EUROPEAN STUDY IN CLINICAL PRACTICE
340. T-17 Sustained virologic response to interferon prevents the lethal consequence of clinical decompensation in patients who develop a hepatocellular carcinoma post antiviral-treatment
341. T-9 2-year effectiveness and safety of tenofovir in 302 NUC-naive patients with chronic hepatitis B: a multicenter European study in clinical practice
342. T-8 Entecavir monotherapy in 418 NUC-naive patients with chronic hepatitis B from field practice: high efficacy and favorable safety profile over 3 years of treatment
343. T-7 The course of bone mineral density in patients with chronic hepatitis B long term treated with nucleos(t)ide analogs: a longitudinal cohort study
344. A POU-domain transcription factor in early stem cells and germ cells of the mammalian embryo
345. Direct transcriptional control of the Dpp target omb by the DNA binding protein Brinker.
346. 753 NUCLEOS(T)IDE ANALOGUES CAN BE SAFELY DISCONTINUED IN CHRONIC HEPATITIS B PATIENTS ACHIEVING HBSAG SEROCLEARANCE
347. 730 PEGBELIVER STUDY: HBSAG DECLINE AT WEEK 24 OF EXTENDED PEGINTERFERON ALFA-2A (PEG-IFNα-2A) THERAPY IS SIGNIFICANTLY ASSOCIATED WITH POST-TREATMENT RESPONSE IN HBEAG-NEGATIVE GENOTYPE D PATIENTS
348. 731 EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 302 NUC-NAIVE PATIENTS WITH CHRONIC HEPATITIS B
349. P.1.95: DUAL CUT-OFF ELASTOGRAPHY TO ASSESS LIVER FIBROSIS IN CHRONIC HEPATITIS B: A COHORT STUDY WITH INTERNAL VALIDATION
350. P.1.48: EFFECTIVENESS AND SAFETY OF TENOFOVIR DISOPROXIL FUMARATE IN FIELD PRACTICE: A MULTICENTER EUROPEAN COHORT STUDY OF 737 PATIENTS WITH CHRONIC HEPATITIS B
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.